Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Nagoya Protocol posing challenges for livestock disease control
Experts say the Protocol is slowing down the production of FMD vaccines.
The agreement is slowing down FMD vaccine production, experts say.

Experts in foot-and-mouth disease (FMD) have criticised the Nagoya Protocol, suggesting that the international agreement has challenged the control of livestock diseases.

The specialists suggest that the legislation, as well as the differing administrative structures across nations, is delaying access to FMD virus isolates and disrupting vaccine production.

The Nagoya Protocol on Access and Benefit Sharing was implemented in 2014, to supplement the Convention on Biological Diversity in achieving fair sharing of the benefits of genetic resource usage. The Protocol, approved or ratified by nearly 140 countries, aimed to incentivise the conservation and sustainable use of genetic resources.

FMD experts from multiple agencies and institutions have now co-written an article voicing their concerns about the impact of the Protocol on the control and treatment of livestock diseases such as FMD.

The article, written by 29 specialists, commends the goals of the Protocol in providing fair and equal access to genetic resource benefits.

However the authors also criticise the access and benefit-sharing legislation, and related administrative structures within nations, for the ‘significant logistical challenges’ posed to the control of transboundary livestock diseases.

The experts say that the Protocol is slowing down access to FMD virus isolates from the field, and affecting the production of new vaccines. This, in turn, delays the development of other tools for surveillance, research and outbreak control.

Dr Don King, who leads the Food and Agriculture Organisation World Reference Laboratory for FMD at The Pirbright Institute, said: ““Our aim is to promote wider awareness of the Nagoya Protocol, and to highlight its impacts on the regular exchange and utilisation of biological materials collected from clinical cases which underpin FMD research activities, and work to develop new epidemiologically relevant vaccines and other diagnostic tools to control the disease.”

“There is an urgent need to clarify the framework and related processes for both users and providers and for a greater science-policy dialogue both within and among countries to ensure a better understanding and more effective implementation of the Nagoya Protocol and related ABS measures.”

The full article has been published in the journal Frontiers of Veterinary Science.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.